Doctors -Image by Moondance from Pixabay

Industry

-

NMD Pharma Reports Positive Data from a Phase I/IIa Clinical Trial of its ClC-1 Chloride Ion Channel Inhibitor NMD670 in Patients with Myasthenia Gravis

Source: NMD Pharma

Ion Channel library
About
Credits

artem@ionchannellibrary.com

© 2023 Artem Kondratskyi

Terms of Use

Privacy policy